Abstract
Diabetic gastroparesis (DGp) is associated with severe symptoms, impaired quality of life, and significant health care utilization.1 Treatment of DGp remains unsatisfactory. Metoclopramide is the only Food and Drug Administration–approved medication for gastroparesis. Gastric electrical stimulation is approved for compassionate use in refractory patients; however, it is invasive, lacks robust supporting evidence, does not consistently improve symptoms, and is associated with serious adverse events.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Paper Title
Journal
Date
